I would like to share with all of you an article on one of my patients that was featured in Ladies Home Journal. I think her story will resonate with all of you.
Recently, I described the rationale for targeting HER2 mutations in non-small cell lung cancer (NSCLC). Most of our experience with HER2 targeted therapy comes from studies in breast cancer. Now, I'd like to introduce you to BRAF, another novel target in NSCLC that is a central component in cell signalling, growth, and division.